Major medical societies broadly support the FDA’s removal of most boxed warnings from menopausal hormone therapy, emphasizing improved access and the importance of individualized risk assessment. The Americas have lost their measles-free status due to persistent outbreaks driven by low vaccination coverage, prompting PAHO to call for renewed immunization efforts and stronger surveillance. A randomized trial in JAMA found that moderate caffeinated coffee intake may reduce recurrence of atrial fibrillation after cardioversion compared with abstinence.

A Rutgers-led trial found that ibuprofen plus acetaminophen provided better pain relief and fewer side effects than opioids following dental surgery, challenging traditional prescribing habits. A Swiss national cohort showed that non–beta-lactam antibiotics nearly doubled surgical-site infection risk compared to beta-lactams, reinforcing their role in prophylaxis. Finally, a meta-analysis confirmed that acetaminophen remains safe during pregnancy when used appropriately, with no proven link to neurodevelopmental disorders.

Drs. Cooper and Rotow review the challenges of CNS involvement in HER2+ NSCLC, emphasizing the importance of baseline and ongoing brain imaging, and the emerging understanding of CNS penetrance for HER2-targeted therapies. They explore strategies for managing brain metastases, including balancing local therapies, including radiation with systemic treatments, and highlight the need for multidisciplinary approaches and further research on CNS activity in clinical trials.

A New England Journal of Medicine study showed a novel chemotherapy regimen, trastuzumab deruxtecan combined with pertuzumab, outperformed the current standard in treating HER2-positive advanced breast cancer, demonstrating better efficacy and tolerability with fewer traditional chemotherapy-related side effects. A JAMA Oncology study by Uppsala University revealed a modest increase in breast cancer risk with hormonal contraceptive use among over two million Swedish women, emphasizing the need for balanced counseling regarding risks and benefits. The REPAIR trial in Denmark, published in the British Medical Journal, demonstrated that a short course of antibiotics significantly reduced clinically important wound complications after vaginal delivery in women with episiotomies or second-degree tears, highlighting its potential benefit in postpartum care.

Drs. Rotow and Cooper explore the evolving landscape of HER2+ NSCLC treatment, highlighting recent advancements in targeted therapies like HER2 TKIs and antibody-drug conjugates. They emphasize the importance of comprehensive biomarker testing, the significance of personalized treatment approaches, and the exciting progress in providing more effective and tolerable second-line therapies for patients. The discussion underscores the field's movement toward precision medicine and the potential for future combination strategies and improved patient outcomes.

Drs. Cooper and Rotow discuss first-line treatment strategies for HER2+ NSCLC, highlighting the importance of comprehensive molecular testing and emerging targeted therapies. Key considerations include the efficacy of antibody-drug conjugates and TKIs, with ongoing clinical trials evaluating their potential as frontline treatments. The discussion emphasizes the need for personalized treatment approaches based on individual patient characteristics, molecular features, and the evolving landscape of HER2-targeted therapies.

Drs. Lynce and Waks explore whether advances in HER2-targeted therapy are making metastatic HER2+ breast cancer potentially curable, highlighting long-term remissions, survival gains from trials, and ongoing studies testing treatment-free remission.

Drs. Waks and Lynce review the PATINA trial, which showed that adding a CDK4/6 inhibitor to HER2-targeted and endocrine therapy improved progression-free survival in triple-positive breast cancer, shaping how this subgroup may be managed.

New research presented at ESMO 2025 confirms that datopotamab deruxtecan significantly improves progression-free and overall survival compared with chemotherapy in advanced triple-negative breast cancer, supporting its role as a first-line standard of care. Updated SELECT trial analyses demonstrate that semaglutide reduces major cardiovascular events by 20% independent of weight loss, suggesting cardioprotective mechanisms beyond adiposity reduction. Long-term data show that HPV vaccination has led to dramatic declines in vaccine-type infections and strong herd protection, although global coverage remains suboptimal.

New research presented at ESMO 2025 confirms that datopotamab deruxtecan significantly improves progression-free and overall survival compared with chemotherapy in advanced triple-negative breast cancer, supporting its role as a first-line standard of care. Updated SELECT trial analyses demonstrate that semaglutide reduces major cardiovascular events by 20% independent of weight loss, suggesting cardioprotective mechanisms beyond adiposity reduction. Long-term data show that HPV vaccination has led to dramatic declines in vaccine-type infections and strong herd protection, although global coverage remains suboptimal.